Grosswald Ralph 4

What Happened
Ralph Grosswald, Senior Vice President of Operations at Dogwood Therapeutics (DWTX), was granted 82,500 derivative awards on 2026-03-05. The filing reports an acquisition price of $0 and classifies the transaction as a derivative award. A footnote clarifies these are stock options that vest one‑third on March 5, 2027 and then 1/24th monthly thereafter.

Key Details

• Transaction date: 2026-03-05; Form 4 filed 2026-03-06 (timely filing).
• Award: 82,500 derivative shares/options; reported acquisition price $0; reported total value $0 on the form.
• Vesting: 1/3 vests on 2027-03-05, then 1/24th each month thereafter (per footnote F1).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• No 10b5-1 plan, tax withholding, or sale noted in this filing.

Context
This was a standard equity compensation grant to an executive (not an open‑market purchase or sale). Such option grants vest over time and only provide value if the company’s stock rises above any exercise price and other exercise conditions are met. This award does not indicate any immediate sale or change in company ownership.